# Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

> **NCT05445128** · PHASE2 · TERMINATED · sponsor: **Ensoma** · enrollment: 1 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **BIOLOGICAL:** MGTA-145
- **DRUG:** Plerixafor

## Key facts

- **NCT ID:** NCT05445128
- **Lead sponsor:** Ensoma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-24
- **Primary completion:** 2022-12-08
- **Final completion:** 2023-02-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety issue.
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445128, "Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05445128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*